Drug Trial Radar · NCT02393248
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Last checked: Nov 19, 2026Latest source record: Jan 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
201
Actual
Start
Feb 27, 2015
Primary completion
Dec 17, 2021
Study completion Dec 17, 2021
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Mar 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Conditions
- Lung Cancer
- Solid Tumor
- Gastric Cancer
- Urothelial Cancer
- Endometrial Cancer
- Multiple Myeloma
- Myeloproliferative Neoplasms
- Breast Cancer
- Cholangiocarcinoma
- UC
- MPN
Interventions
PemigatinibDrug
GemcitabineDrug
PembrolizumabDrug
DocetaxelDrug
TrastuzumabDrug
RetifanlimabDrug
CisplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: up to 763 days
- Part 3: Number of Participants With Any TEAETime frame: up to 869 days
- E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
- EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
- Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
- Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Cedars-Sinai Medical Center
West Hollywood, California
Yale Cancer Center
New Haven, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Hematology Oncology Associates of the Tr
Port Saint Lucie, Florida
Emory University - Winship Cancer Institute
Atlanta, Georgia
University of Michigan Health System
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey
Northwell Health - Monter Cancer Center
New Hyde Park, New York
Montefiore Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University - Wexner Medical Center
Columbus, Ohio
Signal Point Clinical Research Center
Middletown, Ohio
Greenville Health System Cancer Institute
Greenville, South Carolina
Mary Crowley Cancer Research Ctr
Dallas, Texas
Md Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Baylor Scott & White Health
Temple, Texas
The Finsen Centre National Hospital
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.